Continuous oral olanzapine or clozapine treatment initiated in adolescence has differential short- and long-term impacts on antipsychotic sensitivity than those initiated in adulthood.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Wu R;Wu R; Chou S; Chou S; Li M; Li M
  • Source:
    European journal of pharmacology [Eur J Pharmacol] 2024 Jun 05; Vol. 972, pp. 176567. Date of Electronic Publication: 2024 Apr 04.
  • Publication Type:
    Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 1254354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0712 (Electronic) Linking ISSN: 00142999 NLM ISO Abbreviation: Eur J Pharmacol Subsets: MEDLINE
    • Publication Information:
      Publication: 2005- : Amsterdam : Elsevier Science
      Original Publication: Amsterdam, North Holland Pub. Co.
    • Subject Terms:
      Clozapine*/administration & dosage ; Clozapine*/pharmacology ; Olanzapine*/administration & dosage ; Antipsychotic Agents*/administration & dosage ; Antipsychotic Agents*/pharmacology ; Avoidance Learning*/drug effects; Animals ; Male ; Female ; Rats ; Administration, Oral ; Age Factors ; Time Factors ; Behavior, Animal/drug effects ; Benzodiazepines/administration & dosage ; Benzodiazepines/adverse effects ; Benzodiazepines/pharmacology ; Rats, Sprague-Dawley
    • Abstract:
      One of the major discoveries in recent research on antipsychotic drugs is that antipsychotic treatment in adolescence could induce robust long-term alterations in antipsychotic sensitivity that persist into adulthood. These long-term impacts are likely influenced by various factors, including the "diseased" state of animals, sex, type of drugs, mode of drug administration, and age of treatment onset. In this study we compared the short- and long-term behavioral effects of 21-day continuous oral olanzapine (7.5 mg/kg/day) or clozapine (30.0 mg/kg/day) administration in heathy or maternal immune activated adolescent (33-53 days old) or adult (80-100 days old) rats of both sexes. We used a conditioned avoidance response model to assess the drug-induced alterations in antipsychotic sensitivity. Here, we report that while under the chronic drug treatment period, olanzapine progressively increased its suppression of avoidance responding over time, especially when treatment was initiated in adulthood. Clozapine's suppression depended on the age of drug exposure, with treatment initiated in adulthood showing a suppression while that initiated in adolescent did not. After a 17-day drug-free interval, in a drug challenge test, olanzapine treatment initiated in adolescence caused a decrease in drug sensitivity, as reflected by less avoidance suppression (a tolerance effect); whereas that initiated in adulthood appeared to cause an increase (more avoidance suppression, a sensitization effect). Clozapine treatments initiated in both adolescence and adulthood caused a similar tolerance effect. Our findings indicate that the same chronic antipsychotic treatment regimen initiated in adolescence or adulthood can have differential short- and long-term impacts on drug sensitivity.
      Competing Interests: Declaration of competing interest The authors declare no conflict of interests.
      (Copyright © 2024 Elsevier B.V. All rights reserved.)
    • References:
      Behav Brain Res. 2013 Feb 1;238:178-87. (PMID: 23092709)
      Expert Opin Pharmacother. 2018 Sep;19(13):1475-1488. (PMID: 30102079)
      J Psychopharmacol. 2014 Apr;28(4):363-75. (PMID: 24257809)
      J Psychopharmacol. 2010 Jul;24(7):1045-53. (PMID: 19329544)
      Mol Psychiatry. 2005 Jan;10(1):79-104. (PMID: 15289815)
      Brain Res. 2015 Aug 27;1618:122-35. (PMID: 26049127)
      Clin Psychopharmacol Neurosci. 2012 Dec;10(3):168-79. (PMID: 23430396)
      Pharmacol Biochem Behav. 2022 Sep;219:173453. (PMID: 36029928)
      J Neurosci. 2012 Jan 11;32(2):436-51. (PMID: 22238080)
      Brain Res. 2011 Jun 7;1394:24-32. (PMID: 21396352)
      J Psychopharmacol. 2018 Nov;32(11):1252-1263. (PMID: 30136620)
      Biol Psychiatry. 2008 Jul 15;64(2):145-52. (PMID: 18295747)
      Pharmacol Biochem Behav. 2011 Sep;99(3):509-18. (PMID: 21600239)
      Pharmacol Biochem Behav. 2013 Jan;103(3):467-73. (PMID: 23026062)
      Schizophr Bull. 2010 Sep;36(5):900-3. (PMID: 20650931)
      J Psychiatr Res. 2012 Sep;46(9):1199-205. (PMID: 22687817)
      J Pharmacol Exp Ther. 2001 May;297(2):711-7. (PMID: 11303062)
      Biol Psychiatry. 2009 Dec 1;66(11):1038-46. (PMID: 19726031)
      Neuropharmacology. 2016 Sep;108:264-74. (PMID: 27130903)
      Behav Brain Res. 2010 Dec 1;213(2):323-7. (PMID: 20471999)
      Neuropharmacology. 2013 Dec;75:356-64. (PMID: 23954676)
      J Neural Transm (Vienna). 2008 May;115(5):745-53. (PMID: 18193153)
      Pharmacol Biochem Behav. 2011 Jun;98(4):559-69. (PMID: 21402097)
      Neuropsychopharmacology. 2003 Oct;28(10):1778-89. (PMID: 12865897)
      Nat Neurosci. 1999 Oct;2(10):859-61. (PMID: 10491602)
      Brain Behav Immun. 2017 Jul;63:8-20. (PMID: 27423491)
      J Neurosci. 2007 Mar 14;27(11):2979-86. (PMID: 17360921)
      Neuropsychiatr Dis Treat. 2018 Jun 14;14:1569-1583. (PMID: 29950841)
      Mol Psychiatry. 1999 Mar;4(2):145-54. (PMID: 10208446)
      PLoS One. 2013;8(2):e57308. (PMID: 23437365)
      J Psychopharmacol. 2016 Aug;30(8):771-94. (PMID: 27413140)
      Psychopharmacology (Berl). 2010 Sep;212(1):45-57. (PMID: 20623111)
      Pharmacol Rep. 2016 Oct;68(5):1028-35. (PMID: 27428765)
      Pharmacol Biochem Behav. 2011 Mar;98(1):155-60. (PMID: 21194545)
      N Engl J Med. 2002 Aug 1;347(5):314-21. (PMID: 12151468)
      J Psychopharmacol. 2015 Apr;29(4):390-400. (PMID: 25586399)
      Behav Brain Res. 2013 Nov 15;257:286-94. (PMID: 24103641)
      Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72. (PMID: 14642974)
      Neurosci Biobehav Rev. 2020 Jun;113:546-567. (PMID: 32320814)
      J Neurosci. 2003 Jan 1;23(1):297-302. (PMID: 12514227)
      Behav Pharmacol. 2012 Aug;23(4):380-91. (PMID: 22732209)
      Front Neurosci. 2022 Dec 16;16:1071976. (PMID: 36590294)
      Behav Brain Res. 2021 Apr 9;403:113145. (PMID: 33515643)
      Eur J Pharmacol. 2009 Jan 14;602(2-3):334-42. (PMID: 19059234)
      Psychopharmacology (Berl). 2015 Apr;232(7):1219-30. (PMID: 25288514)
      Behav Brain Res. 2014 Oct 15;273:166-76. (PMID: 25093543)
      Neurochem Res. 2003 Feb;28(2):235-41. (PMID: 12608697)
      NeuroRx. 2006 Jan;3(1):10-21. (PMID: 16490410)
      Behav Brain Res. 2016 Jul 1;307:176-85. (PMID: 27059335)
      Int J Mol Sci. 2016 Nov 22;17(11):. (PMID: 27879654)
      Behav Brain Res. 2017 Jun 15;328:186-194. (PMID: 28412306)
      JAMA Psychiatry. 2020 Jul 1;77(7):674-683. (PMID: 32101271)
      Neuropsychopharmacology. 2013 Feb;38(3):513-24. (PMID: 23132270)
      Pharmacol Biochem Behav. 2017 May;156:39-47. (PMID: 28389140)
      Brain Res Dev Brain Res. 1995 Nov 21;89(2):167-72. (PMID: 8612321)
      J Psychopharmacol. 2016 Aug;30(8):749-70. (PMID: 27371498)
      Pharmacol Res. 2017 Jul;121:1-13. (PMID: 28414178)
      J Am Acad Child Adolesc Psychiatry. 2016 Jun;55(6):456-468.e4. (PMID: 27238064)
      J Neural Transm (Vienna). 2012 Apr;119(4):497-505. (PMID: 21986871)
      Psychopharmacol Bull. 1989;25(3):390-2. (PMID: 2576319)
      Biol Psychiatry. 2006 Mar 15;59(6):546-54. (PMID: 16256957)
      Prog Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:67-75. (PMID: 24942467)
      Neuropsychopharmacology. 2007 Feb;32(2):263-72. (PMID: 16738541)
      Brain Behav Immun. 2012 Feb;26(2):353-63. (PMID: 22154704)
      Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:177-85. (PMID: 24140929)
      Psychopharmacology (Berl). 2014 Apr;231(8):1649-1659. (PMID: 24363078)
      Neuropsychobiology. 1999;39(2):86-91. (PMID: 10072665)
      Neurosci Biobehav Rev. 1999;23(6):851-62. (PMID: 10541060)
      Eur Neuropsychopharmacol. 2004 Aug;14(4):340-6. (PMID: 15163446)
      Behav Brain Res. 2008 Jun 26;190(1):156-9. (PMID: 18367260)
      Int J Neuropsychopharmacol. 2013 Aug;16(7):1599-609. (PMID: 23351612)
      Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):175-82. (PMID: 22476004)
      Am J Psychiatry. 1998 Jun;155(6):768-73. (PMID: 9619148)
      Cereb Cortex. 2000 Oct;10(10):1014-27. (PMID: 11007552)
      Behav Pharmacol. 2009 Mar;20(2):184-94. (PMID: 19322074)
      Exp Neurol. 2016 Sep;283(Pt A):142-50. (PMID: 27302677)
      Eur J Pharmacol. 2010 May 25;634(1-3):68-76. (PMID: 20184878)
      J Pharmacol Exp Ther. 2003 May;305(2):625-31. (PMID: 12606608)
      Am J Psychiatry. 1995 May;152(5):698-703. (PMID: 7726309)
      J Psychiatr Res. 2005 May;39(3):311-23. (PMID: 15725430)
      Behav Pharmacol. 2012 Feb;23(1):66-79. (PMID: 22157143)
    • Grant Information:
      R03 HD079870 United States HD NICHD NIH HHS
    • Contributed Indexing:
      Keywords: Adolescent; Adult; Clozapine; Conditioned avoidance response; Maternal immune activation; Olanzapine
    • Accession Number:
      J60AR2IKIC (Clozapine)
      N7U69T4SZR (Olanzapine)
      0 (Antipsychotic Agents)
      12794-10-4 (Benzodiazepines)
    • Publication Date:
      Date Created: 20240406 Date Completed: 20240426 Latest Revision: 20240527
    • Publication Date:
      20240527
    • Accession Number:
      PMC11128075
    • Accession Number:
      10.1016/j.ejphar.2024.176567
    • Accession Number:
      38582275